625 related articles for article (PubMed ID: 23715113)
1. Efficacy of antitumor necrosis factor(α) agents on patients with ankylosing spondylitis.
Ren L; Li J; Luo R; Tang R; Zhu S; Wan L
Am J Med Sci; 2013 Dec; 346(6):455-61. PubMed ID: 23715113
[TBL] [Abstract][Full Text] [Related]
2. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
Callhoff J; Sieper J; Weiß A; Zink A; Listing J
Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
6. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis.
Machado MA; Barbosa MM; Almeida AM; de Araújo VE; Kakehasi AM; Andrade EI; Cherchiglia ML; Acurcio Fde A
Rheumatol Int; 2013 Sep; 33(9):2199-213. PubMed ID: 23686218
[TBL] [Abstract][Full Text] [Related]
7. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
Braun J; Baraliakos X; Listing J; Davis J; van der Heijde D; Haibel H; Rudwaleit M; Sieper J
Arthritis Rheum; 2007 May; 57(4):639-47. PubMed ID: 17471540
[TBL] [Abstract][Full Text] [Related]
8. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A
Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401
[TBL] [Abstract][Full Text] [Related]
9. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database.
Wendling D; Joshi A; Reilly P; Jalundhwala YJ; Mittal M; Bao Y
Curr Med Res Opin; 2014 Dec; 30(12):2515-21. PubMed ID: 25252590
[TBL] [Abstract][Full Text] [Related]
10. Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.
Armstrong N; Joore M; van Asselt T; Misso K; Manning N; Tomini F; Kleijnen J; Riemsma R
Pharmacoeconomics; 2013 May; 31(5):415-25. PubMed ID: 23580355
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
Rudwaleit M; Van den Bosch F; Kron M; Kary S; Kupper H
Arthritis Res Ther; 2010; 12(3):R117. PubMed ID: 20553600
[TBL] [Abstract][Full Text] [Related]
12. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
Lanfant-Weybel K; Lequerré T; Vittecoq O
Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal anti-TNF antibodies can elevate hemoglobin level in patients with ankylosing spondylitis.
Bes C; Yazici A; Soy M
Rheumatol Int; 2013 Jun; 33(6):1415-8. PubMed ID: 23143665
[TBL] [Abstract][Full Text] [Related]
14. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.
Paccou J; Baclé-Boutry MA; Solau-Gervais E; Bele-Philippe P; Flipo RM
J Rheumatol; 2012 Jul; 39(7):1418-23. PubMed ID: 22707611
[TBL] [Abstract][Full Text] [Related]
15. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis.
Arends S; Lebbink HR; Spoorenberg A; Bungener LB; Roozendaal C; van der Veer E; Houtman PM; Griep EN; Limburg PC; Kallenberg CG; Wolbink GJ; Brouwer E
Clin Exp Rheumatol; 2010; 28(5):661-8. PubMed ID: 20822711
[TBL] [Abstract][Full Text] [Related]
16. Etanercept: new indication. For ankylosing spondylitis: another option.
Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387
[TBL] [Abstract][Full Text] [Related]
17. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.
Glintborg B; Østergaard M; Krogh NS; Tarp U; Manilo N; Loft AG; Hansen A; Schlemmer A; Fana V; Lindegaard HM; Nordin H; Rasmussen C; Ejstrup L; Jensen DV; Petersen PM; Hetland ML
Ann Rheum Dis; 2013 Jul; 72(7):1149-55. PubMed ID: 22941767
[TBL] [Abstract][Full Text] [Related]
18. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab.
Cohen JD; Ferreira R; Jorgensen C
J Rheumatol; 2011 Jul; 38(7):1527. PubMed ID: 21724733
[No Abstract] [Full Text] [Related]
19. [Anti-TNFα therapy in ankylosing spondylitis: symptom control and structural damage modification].
Andreu JL; Otón T; Sanz J
Reumatol Clin; 2011; 7(1):51-5. PubMed ID: 21794779
[TBL] [Abstract][Full Text] [Related]
20. [Anti-TNF alpha in the treatment of psoriatic arthritis].
Claudepierre P; Wendling D; Cohen JD
Presse Med; 2006 Apr; 35(4 Pt 2):647-55. PubMed ID: 16614610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]